Providers’ communication skills play a key role in encouraging breast cancer survivors to report symptoms and adhere to long-term treatments such as adjuvant endocrine therapy (AET). The purpose of this study was to examine provider perspectives on patient-provider communication regarding AET symptom management and to explore whether provider perspectives vary across the multi-disciplinary team of providers involved in survivorship care
Background/Purpose: Daily adjuvant endocrine therapy (AET) is prescribed to women for 5–10 years for...
Introduction : Despite evidence of the efficacy of Adjuvant Endocrine Therapy (AET) in reducing the ...
PurposeAccording to the Institute of Medicine, high-quality cancer care should include effective com...
Adherence to adjuvant endocrine therapy (AET) for breast cancer is suboptimal. The purpose of this s...
Background: Adjuvant endocrine therapy (AET) is highly efficacious, significantly reducing breast ca...
Background: Adjuvant endocrine therapy (AET) significantly decreases the risk of br...
Stephanie B Wheeler,1,2 Megan C Roberts,1 Diane Bloom,1 Katherine E Reeder-Hayes,2,3 Maya Espada,1 J...
Adjuvant endocrine therapy (ET) can reduce the risk of recurrence among females with hormone recepto...
Jo Brett,1 Mary Boulton,1 Debbie Fenlon,2 Nick J Hulbert-Williams,3 Fiona M Walter,4 Peter Donnelly,...
Adjuvant endocrine therapy (AET) has substantially improved the mortality rate among breast cancer s...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
Since the rate of persistence to adjuvant endocrine therapy such as 5-year aromatase inhibitors (AI)...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Background: Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality of women...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Background/Purpose: Daily adjuvant endocrine therapy (AET) is prescribed to women for 5–10 years for...
Introduction : Despite evidence of the efficacy of Adjuvant Endocrine Therapy (AET) in reducing the ...
PurposeAccording to the Institute of Medicine, high-quality cancer care should include effective com...
Adherence to adjuvant endocrine therapy (AET) for breast cancer is suboptimal. The purpose of this s...
Background: Adjuvant endocrine therapy (AET) is highly efficacious, significantly reducing breast ca...
Background: Adjuvant endocrine therapy (AET) significantly decreases the risk of br...
Stephanie B Wheeler,1,2 Megan C Roberts,1 Diane Bloom,1 Katherine E Reeder-Hayes,2,3 Maya Espada,1 J...
Adjuvant endocrine therapy (ET) can reduce the risk of recurrence among females with hormone recepto...
Jo Brett,1 Mary Boulton,1 Debbie Fenlon,2 Nick J Hulbert-Williams,3 Fiona M Walter,4 Peter Donnelly,...
Adjuvant endocrine therapy (AET) has substantially improved the mortality rate among breast cancer s...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
Since the rate of persistence to adjuvant endocrine therapy such as 5-year aromatase inhibitors (AI)...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Background: Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality of women...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Background/Purpose: Daily adjuvant endocrine therapy (AET) is prescribed to women for 5–10 years for...
Introduction : Despite evidence of the efficacy of Adjuvant Endocrine Therapy (AET) in reducing the ...
PurposeAccording to the Institute of Medicine, high-quality cancer care should include effective com...